Literature DB >> 28581205

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial.

Prasanna Sooriakumaran1,2.   

Abstract

This is the Protocol of the ethically-approved TRoMbone study.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; oligometastases; prostate cancer; radical prostatectomy

Mesh：

Substances：

Year:  2017        PMID： 28581205     DOI： 10.1111/bju.13925

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


  14 in total

1.  Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

Authors:  Alan I So; Kim N Chi; Brita Danielson; Neil E Fleshner; Anil Kapoor; Tamim Niazi; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala Sridhar; Eric Vigneault; Fred Saad
Journal:  Can Urol Assoc J       Date:  2019-12-05       Impact factor: 1.862

2.  Re: A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills? From Slaoui et al., World J urol 2019. Long-term safety of local radiation therapy of newly diagnosed low burden metastatic prostate cancer: an unaddressed concern.

Authors:  Bernardo Rocco; Sighinolfi Maria Chiara
Journal:  World J Urol       Date:  2019-03-16       Impact factor: 4.226

Review 3.  Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Authors:  Gargi Kothari; Piet Ost; Patrick Cheung; Pierre Blanchard; Alison C Tree; Nicholas J van As; Simon S Lo; Drew Moghanaki; Andrew Loblaw; Shankar Siva
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.075

Review 4.  The role of surgery in high risk and advanced prostate cancer: A narrative review.

Authors:  Chloe Sheila Dayan Roy; Ashwin Sachdeva; Gokul Vignesh Kandaswamy; Bhavan Prasad Rai
Journal:  Turk J Urol       Date:  2020-10-30

Review 5.  Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.

Authors:  Marlon Perera; Matthew J Roberts; Laurence Klotz; Celestia S Higano; Nathan Papa; Shomik Sengupta; Damien Bolton; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2020-06-30       Impact factor: 14.432

Review 6.  Imaging modalities in synchronous oligometastatic prostate cancer.

Authors:  Jurgen J Futterer; Cristian Surcel; Roderick van den Bergh; Hendrik Borgmann; Alberto Briganti; Giorgio Gandaglia; Alexander Kretschmer; Piet Ost; Prasanna Sooriakumaran; Derya Tilki; Massimo Valerio; Guillaume Ploussard; Pieter J L De Visschere; Igor Tsaur
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

Review 7.  Cytoreductive treatment strategies for de novo metastatic prostate cancer.

Authors:  Martin J Connor; Taimur T Shah; Gail Horan; Charlotte L Bevan; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Clin Oncol       Date:  2019-11-11       Impact factor: 66.675

Review 8.  Harnessing the potential of multimodal radiotherapy in prostate cancer.

Authors:  Yiannis Philippou; Hanna Sjoberg; Alastair D Lamb; Philip Camilleri; Richard J Bryant
Journal:  Nat Rev Urol       Date:  2020-05-01       Impact factor: 14.432

Review 9.  Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.

Authors:  Kyo Chul Koo; Prokar Dasgupta
Journal:  Yonsei Med J       Date:  2018-07       Impact factor: 2.759

10.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Authors:  Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet       Date:  2018-10-21       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.